Welcome to our dedicated page for Precision Biosciences SEC filings (Ticker: DTIL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Precision BioSciences, Inc. (Nasdaq: DTIL) provides access to the company’s official regulatory disclosures as a clinical stage gene editing company. These documents offer detailed information on its ARCUS-based in vivo gene editing programs, financial condition, capital raising activities, and other material events relevant to shareholders and analysts.
Among the key filings are Current Reports on Form 8-K, which Precision uses to report significant developments. Examples include an 8-K describing an underwritten offering of common stock, pre-funded warrants, and warrants, with net proceeds intended to fund ongoing and planned research and development, working capital, and general corporate purposes. Other 8-Ks furnish press releases on clinical data from the ELIMINATE-B trial of PBGENE-HBV, updates on PBGENE-DMD, quarterly financial results, and executive employment arrangements.
Filings related to PBGENE-HBV summarize clinical findings such as dose-dependent antiviral activity, reductions in hepatitis B surface antigen (HBsAg), biopsy evidence of ARCUS-mediated viral DNA editing, and safety data across multiple cohorts. These reports help readers understand how Precision evaluates safety, efficacy, and dosing strategy for its hepatitis B program. Additional disclosures describe regulatory designations, trial expansion plans, and the structure of ongoing Phase 1/2a studies.
For capital markets activity, SEC filings detail the terms of equity offerings, including the number of shares and warrants issued, exercise prices, and intended use of proceeds. Exhibits to these filings may include underwriting agreements, warrant forms, and legal opinions on the validity of securities.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight the most important points from lengthy documents, helping users quickly grasp the implications of new 8-Ks and other reports. Real-time updates from EDGAR, combined with structured access to items such as clinical trial updates, financing transactions, and governance changes, make this page a focused resource for reviewing Precision BioSciences’ regulatory history and ongoing obligations.
Precision BioSciences President and CEO Michael Amoroso reported a mix of RSU vesting and a tax-related share sale. On February 17, 2026, 67,797 Restricted Stock Units vested, with each RSU converting into one share of common stock. On February 18, 2026, he sold 20,559 common shares at $3.84 per share in an open-market transaction executed under a pre-arranged Rule 10b5-1 plan, solely to cover tax withholding and related fees from the RSU vesting. Following these transactions, he directly held 243,392 shares of common stock and 135,593 RSUs, which continue to vest in three substantially equal annual installments beginning February 17, 2026, contingent on continued service.
Precision Biosciences Chief Financial Officer John Alexander reported RSU vesting and related share transactions. On February 17, 2026, 27,584 Restricted Stock Units vested, each representing a right to receive one share of common stock, and were settled into 27,584 common shares at a stated price of $0.00 per share.
On February 18, 2026, he sold 8,149 common shares at $3.84 per share in an open-market transaction executed under a Rule 10b5-1 trading plan. According to the footnotes, this was a sell-to-cover transaction, with shares sold only to satisfy tax withholding and related fees from the RSU vesting.
After these transactions, he directly held 125,883 shares of common stock and 55,166 RSUs, with the RSUs scheduled to vest in three substantially equal annual installments beginning on February 17, 2026, subject to his continued service with the company.
PRECISION BIOSCIENCES INC General Counsel and Secretary Dario Scimeca reported RSU vesting and a related tax sale of common stock. On February 17, 2026, 16,667 Restricted Stock Units vested and converted into 16,667 shares of common stock, increasing his direct holdings. Each RSU represents a right to receive one common share.
On February 18, 2026, he sold 4,925 common shares in an open-market transaction at $3.84 per share under a pre-established Rule 10b5-1 trading plan. The sale was a "sell-to-cover" transaction, with shares sold only to cover tax withholding obligations and related fees from the RSU vesting.
Precision BioSciences Chief Research Officer J. Jefferson Smith reported RSU vesting and a related tax sale of common stock. On February 17, 2026, 16,667 Restricted Stock Units vested, each representing one share of common stock, as part of an award scheduled to vest in three equal annual installments beginning on that date.
In connection with this vesting, on February 18, 2026 he executed an open-market sell-to-cover of 4,925 common shares at $3.84 per share under a pre-established Rule 10b5-1 plan, solely to satisfy tax withholding and related fees. After these transactions, he directly held 121,926 common shares and 33,333 RSUs, with an additional 7,931 common shares held indirectly through a charitable remainder unitrust.
DTIL reported Form 144 transactions involving restricted stock vesting and a recent resale. The filing shows 4,925 common shares listed under "Securities To Be Sold" with an event date of
DTIL reported an insider sale notice for common stock under Form 144. The filing lists 4,925 shares as restricted stock vesting to be sold on
DTIL reported a Form 144 filing in which Michael Amoroso indicated a sale of 34,799 common shares on
DTIL insider John A. Kelly filed a Form 144 reporting a proposed sale of 8,149 common shares that vested as restricted stock on
Tang Capital Management and related entities report that they no longer own any Precision BioSciences, Inc. common stock. In Amendment No. 3 to their Schedule 13G, they state beneficial ownership of 0 shares, representing 0% of the company’s common stock as of December 31, 2025.
Each reporting person lists zero sole or shared voting power and zero sole or shared dispositive power over Precision BioSciences shares. They also certify that any securities previously held were not acquired or held to change or influence control of the company.
Lynx1 Capital Management LP and Weston Nichols report beneficial ownership of 993,913 shares of Precision BioSciences, Inc. common stock, equal to 4.1% of the class as of the calculation date. They hold shared voting and dispositive power over all reported shares, with no sole authority.
The ownership percentage is based on 24,071,751 shares of common stock outstanding, combining 10,815,000 shares issued in a recent offering with 13,256,751 shares outstanding as of October 29, 2025. The reporting persons certify the position is not held to change or influence control of the company.